Development of polyfunctionalized biochar modified with manganese oxide and sulfur for immobilizing Hg(II) and Pb(II) in water and soil and improving soil health

Article

作者: Li, Ronghua ; Lv, Xiaoyong ; Wu, Xuan ; Huang, Hui ; Zhang, Han ; Zhang, Zhibo ; Tang, Kuok Ho Daniel ; Li, You ; Guo, Zhiqiang ; Wu, Weilong

Mercury (Hg) and lead (Pb) pose significant risks to human health due to their high toxicity and bioaccumulative properties. This study aimed to develop a novel biochar composite (HMB-S), polyfunctionalized with manganese dioxide (α-MnO₂) and sulfur functional groups, for the effective immobilization of Hg(II) and Pb(II) from contaminated environments. HMB-S demonstrated superior adsorption capacities of 190.1 mg/g for Hg(II) and 259.9 mg/g for Pb(II), which significantly surpasses the capacities of unmodified biochar (HB) and biochar functionalized solely with Mn (HMB). Mechanistic studies revealed that the immobilization of these metals by HMB-S involved ion exchange, mineral precipitation, surface complexation, and electrostatic interactions. In soil incubation experiments, HMB-S significantly decreased the levels of extractable Hg(II) and Pb(II) compared to the control, reducing the mobility of these metals and converting 17 % of Hg(II) and 26 % of Pb(II) into less bioavailable residual forms. Pot experiments confirmed that all tested biochar materials (HB, HMB, and HMB-S) promoted spinach growth in contaminated soils, with HMB-S being the most effective at lowering Hg(II) and Pb(II) uptake by plants. Additionally, analysis of soil microbial communities indicated that HMB-S altered community composition and increased the relative abundance of metal-resistant bacteria. These findings highlight the potential of polyfunctionalized biochar HMB-S as an effective remediation strategy for Hg and Pb contamination in soil and aqueous environments.

2024-11-01·Ageing Research Reviews

Nutritional factors and physical frailty: Highlighting the role of functional nutrients in the prevention and treatment

Review

作者: Sahebkar, Amirhossein ; Karav, Sercan ; Ziaei, Rahele ; Bagherniya, Mohammad ; Shahdadian, Farnaz

Physical frailty, an age-related decline in the physiological capacity and function of various organs, is associated with higher vulnerability to unfavorable health outcomes. The mechanisms proposed for physical frailty including increased inflammation and oxidative stress are closely related to nutritional status. In addition to traditional nutritional factors such as protein malnutrition and nutrient deficiencies, emerging evidence has focused on the role of functional nutrients including polyphenols, carotenoids, probiotics, prebiotics, omega-3 long-chain polyunsaturated fatty acids (n-3 PUFAs), β-hydroxy-β-methylbutyrate (HMB), coenzyme Q10 (CoQ10), and L-carnitine in modifying the risk of physical frailty syndrome. Although several clinical trials have suggested the beneficial effects of supplementation with polyphenols, HMB, and prebiotics on frailty indices, the current evidence is still not robust to support recommendations on the routine clinical use of such functional nutrients for the management of frailty. Similarly, the association between CoQ10 and frailty was mainly assessed in observational studies, and more randomized controlled trials are needed in this regard. A limited number of studies have reported the beneficial effect of L-carnitine supplementation on frailty indices. Since carnitine is mainly found in skeletal muscle and its measurement is thus challenging due to ethical constraints, it is necessary to examine the effect of different doses of L-carnitine on frailty and its indices in future studies. A large number of interventional studies evaluated the impact of n-3 PUFA supplementation on physical frailty in the elderly and many of them reported improved physical performance following supplementation, especially when combined with resistance training programs. Although promising findings from experimental and observational studies have been reported on functional nutrients, high-quality evidence from randomized controlled trials as well as detailed mechanistic studies are still required to affirm their role in the prevention and/or treatment of physical frailty. This review aims to describe the current state of research on functional nutrients that may modify the development or prognosis of frailty syndrome.

2024-10-01·Clinical Nutrition

A systematic review to assess the impact of amino acids or their derivatives on skeletal muscle wasting in critically ill patients

Review

作者: Deane, Adam M ; Rooyackers, Olav ; Wittholz, Kym ; Karahalios, Amalia ; Deane, Adam M. ; Fetterplace, Kate ; Bidgood, Emma ; Mclean, Alistair ; McLean, Alistair

BACKGROUNDIt is plausible that supplementation with specific amino acids or metabolites could attenuate skeletal muscle wasting during critical illness. The aim of this systematic review was to explore if amino acids or their derivatives impact skeletal muscle wastage in critically ill adults.METHODSFour databases were systematically searched to identify randomised control trials which delivered enteral supplemental amino acids, or their metabolites compared with placebo, standard care or no intervention, to critically ill patients and reported outcomes of skeletal muscle mass, plasma amino acids, nitrogen balance, or muscle strength. Two authors independently completed screening, data extraction, and risk of bias assessment using the Cochrane Risk of Bias 2 Tool. A meta-analysis was planned but heterogeneity in the type of intervention used and outcome assessment precluded this. Therefore, data were synthesised using vote counting.RESULTSThirty randomised control trials, comprising 1976 patients were included. The most frequently studied interventional amino acid or metabolite was glutamine (n = 12 trials), a combination (n = 9), arginine (n = 6), β-hydroxy β-methylbutyrate (HMB) (n = 2) or ornithine (n = 1). Six trials (including 284 participants) measured skeletal muscle following supplementation, four of which used HMB alone or in combination as the intervention. Of these, one trial observed an attenuation of muscle wasting with a combination of amino acids, one observed an exacerbation of muscle wasting with HMB, three trials observed no impact on muscle wasting with HMB or a combination of amino acids and one trial reported no information.CONCLUSIONSix trials have investigated the effect of enteral amino acid or amino acid metabolite supplementation on muscle mass in critically ill. Heterogeneity of interventions, outcome assessments and direction of effects limits the certainty regarding the effect of supplemental amino acids, or their metabolites, on skeletal muscle wasting during critical illness. The trial protocol is registered on PROSPERO (CRD42021275989).

100 项与 Beta-Hydroxy-Beta-Methylbutyrate 相关的药物交易

登录后查看更多信息